Accès gratuit
Numéro
Med Sci (Paris)
Volume 28, Numéro 12, Décembre 2012
Page(s) 1095 - 1101
Section M/S Revues
DOI https://doi.org/10.1051/medsci/20122812020
Publié en ligne 21 décembre 2012
  1. Lander ES, Linton LM, Birren B, et al. Initial sequencing and analysis of the human genome. Nature 2001 ; 409 : 860–921. [CrossRef] [PubMed]
  2. Altshuler DM, Gibbs RA, Peltonen L, et al. Integrating common and rare genetic variation in diverse human populations. Nature 2010 ; 467 : 52–58. [CrossRef] [PubMed]
  3. Durbin RM, Abecasis GR, Altshuler DL, et al. A map of human genome variation from population-scale sequencing. Nature 2010 ; 467 : 1061–1073. [CrossRef] [PubMed]
  4. Barreiro LB, Laval G, Quach H, et al. Natural selection has driven population differentiation in modern humans. Nat Genet 2008 ; 40 : 340–345. [CrossRef] [PubMed]
  5. Casanova JL, Abel L. Inborn errors of immunity to infection: the rule rather than the exception. J Exp Med 2005 ; 202 : 197–201. [CrossRef] [PubMed]
  6. Barreiro LB, Quintana-Murci L. From evolutionary genetics to human immunology: how selection shapes host defence genes. Nat Rev Genet 2010 ; 11 : 17–30. [CrossRef] [PubMed]
  7. Quintana-Murci L, Alcais A, Abel L, Casanova JL. Immunology in natura: clinical, epidemiological and evolutionary genetics of infectious diseases. Nat Immunol 2007 ; 8 : 1165–1171. [CrossRef] [PubMed]
  8. Nielsen R, Hellmann I, Hubisz M, et al. Recent and ongoing selection in the human genome. Nat Rev Genet 2007 ; 8 : 857–868. [CrossRef] [PubMed]
  9. Sabeti PC, Schaffner SF, Fry B, et al. Positive natural selection in the human lineage. Science 2006 ; 312 : 1614–1620. [CrossRef] [PubMed]
  10. Delneste Y, Beauvillain C, Jeannin P. Immunité naturelle : structure et fonction des Toll-like receptors. Med Sci (Paris) 2007 ; 23 : 67–73. [CrossRef] [EDP Sciences] [PubMed]
  11. Barreiro LB, Ben-Ali M, Quach H, et al. Evolutionary dynamics of human Toll-like receptors, their different contributions to host defense. PLoS Genet 2009 ; 5 : e1000562. [CrossRef] [PubMed]
  12. Isaacs A, Lindenmann J. Virus interference. I. The interferon. Proc R Soc Lond B Biol Sci 1957 ; 147 : 258–267. [CrossRef] [PubMed]
  13. Pestka S, Krause CD, Walter MR. Interferons, interferon-like cytokines, and their receptors. Immunol Rev 2004 ; 202 : 8–32. [CrossRef] [PubMed]
  14. Uze G, Schreiber G, Piehler J, Pellegrini S. The receptor of the type I interferon family. Curr Top Microbiol Immunol 2007 ; 316 : 71–95. [CrossRef] [PubMed]
  15. Kotenko SV, Gallagher G, Baurin VV, et al. IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol 2003 ; 4 : 69–77. [CrossRef] [PubMed]
  16. Kotenko SV, Krause CD, Izotova LS, et al. Identification and functional characterization of a second chain of the interleukin-10 receptor complex. EMBO J 1997 ; 16 : 5894–5903. [CrossRef] [PubMed]
  17. Zhang SY, Boisson-Dupuis S, Chapgier A, et al. Inborn errors of interferon (IFN)-mediated immunity in humans: insights into the respective roles of IFN-alpha/beta, IFN-gamma, and IFN-lambda in host defense. Immunol Rev 2008 ; 226 : 29–40. [CrossRef] [PubMed]
  18. Filipe-Santos O, Bustamante J, Chapgier A, et al. Inborn errors of IL-12/23- and IFN-gamma-mediated immunity: molecular, cellular, and clinical features. Semin Immunol 2006 ; 18 : 347–361. [CrossRef] [PubMed]
  19. Chapgier A, Wynn RF, Jouanguy E, et al. Human complete Stat-1 deficiency is associated with defective type I and II IFN responses in vitro but immunity to some low virulence viruses in vivo. J Immunol 2006 ; 176 : 5078–5083. [PubMed]
  20. Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009 ; 461 : 399–401. [CrossRef] [PubMed]
  21. Thomas DL, Thio CL, Martin MP, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009 ; 461 : 798–801. [CrossRef] [PubMed]
  22. Labie D, Gilgenkrantz H. Variants génétiques du gène IL28B et élimination du virus de l’hépatite C. Med Sci (Paris) 2010 ; 26 : 225–226. [CrossRef] [EDP Sciences] [PubMed]
  23. Tanaka Y, Nishida N, Sugiyama M, et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009 ; 41 : 1105–1109. [CrossRef] [PubMed]
  24. Manry J, Laval G, Patin E, et al. Evolutionary genetic dissection of human interferons. J Exp Med 2011 ; 208 : 2747–2759. [CrossRef] [PubMed]
  25. Genin P, Vaccaro A, Civas A. The role of differential expression of human interferon – a genes in antiviral immunity. Cytokine Growth Factor Rev 2009 ; 20 : 283–295. [CrossRef] [PubMed]
  26. Trinchieri G. Type I interferon: friend or foe?. J Exp Med 2010 ; 207 : 2053–2063. [CrossRef] [PubMed]
  27. Foster GR, Rodrigues O, Ghouze F, et al. Different relative activities of human cell-derived interferon-alpha subtypes: IFN-alpha 8 has very high antiviral potency. J Interferon Cytokine Res 1996 ; 16 : 1027–1033. [PubMed]
  28. Jaks E, Gavutis M, Uze G, et al. Differential receptor subunit affinities of type I interferons govern differential signal activation. J Mol Biol 2007 ; 366 : 525–539. [CrossRef] [PubMed]
  29. Lavoie TB, Kalie E, Crisafulli-Cabatu S, et al. Binding and activity of all human alpha interferon subtypes. Cytokine 2011 ; 56 : 282–289. [CrossRef] [PubMed]
  30. Coccia EM, Severa M, Giacomini E, et al. Viral infection and Toll-like receptor agonists induce a differential expression of type I and lambda interferons in human plasmacytoid and monocyte-derived dendritic cells. Eur J Immunol 2004 ; 34 : 796–805. [CrossRef] [PubMed]
  31. Genin P, Lin R, Hiscott J, Civas A. Differential regulation of human interferon A gene expression by interferon regulatory factors 3 and 7. Mol Cell Biol 2009 ; 29 : 3435–3450. [CrossRef] [PubMed]
  32. Manry J, Laval G, Patin E, et al. Evolutionary genetics evidence of an essential, nonredundant role of the IFN-gamma pathway in protective immunity. Hum Mutat 2011 ; 32 : 633–642. [CrossRef] [PubMed]
  33. O’Brien TR. Interferon-alfa, interferon-lambda and hepatitis C. Nat Genet 2009 ; 41 : 1048–1050. [CrossRef] [PubMed]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.